Shareholder Update
Filed with ASX · · 3 pages · English
• Commercial launch of Avantect®Pancreatic and Ovarian cancer testing at Sydney Breast Clinic – over 1,000 registered enquiries, 60 bookings and 20 tests during first eleven days of launch • BCAL working with Sonic Healthcare to roll out testing through pathology sites in N SW, QLD and VIC in February • Unit test price of $1,495 per test ($1,995 for combined Pancreatic/Ovarian testing) generating
BCAL Diagnostics Limited on 6ix
Earlier from BCAL Diagnostics
- Quarterly Activities/Appendix 4C Cash Flow Report
- BCAL Early Cancer Detection Tests Update
- BCAL Establishes $10m Convertible Note Facility Revised
- BCAL Establishes $10 million Convertible Note Facility
- BCAL and ClearNote Partner on Early Cancer Detection Tests
Later from BCAL Diagnostics
- Half Yearly Report and Accounts
- BCAL Accelerates Rollout of Avantect Early Detection Tests
- BCAL Appoints Anne-Louise Arnett as Chief Executive Officer
- BCAL Launches Early Detection Cancer Platform
- BCAL Develops New Blood Test for Breast Cancer Recurrence
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics